Patents by Inventor Bailin LEI

Bailin LEI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the Degradation of EGFR Kinase
    Publication number: 20240425523
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, methods of preparation, and uses thereof.
    Type: Application
    Filed: May 30, 2024
    Publication date: December 26, 2024
    Inventors: Huaqing Liu, Bailin Lei, Yizhou Zhao, Xinzhu Qi, Guanjun Liu, Zhiwei Wang
  • DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20240368203
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: July 12, 2024
    Publication date: November 7, 2024
    Applicant: BeiGene, Ltd.
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Yizhou ZHAO, Zhiwei WANG
  • Compounds for the Degradation of EGFR Kinase
    Publication number: 20240342292
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: May 29, 2024
    Publication date: October 17, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Bailin Lei, Huaqing Liu, Songzhe Han, Yizhou Zhao, Zhiwei Wang, Guanjun Liu, Haijun Liu
  • (R)-Glutarimide CRBN Ligands and Methods of Use
    Publication number: 20240207267
    Abstract: Disclosed herein are compounds for binding and modulating the activity of cereblon (CRBN), and methods of use. The present invention also provides compounds that can be used as synthetic intermediates in the preparation of bifunctional compounds for use in targeted protein degradation. The present compounds are thus useful for the treatment or prophylaxis of tumors and cancers.
    Type: Application
    Filed: December 20, 2023
    Publication date: June 27, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Bailin Lei, Huaqing Liu, Songzhe Han, Changxin Huo, Zhiwei Wang
  • EGFR DEGRADERS AND METHODS OF USE
    Publication number: 20240165243
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: February 9, 2022
    Publication date: May 23, 2024
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • EGFR Degraders and Associated Methods of Use
    Publication number: 20240131167
    Abstract: Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.
    Type: Application
    Filed: October 30, 2023
    Publication date: April 25, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Bailin Lei, Huaqing Liu, Songzhe Han, Zhiwei Wang
  • BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE
    Publication number: 20240025902
    Abstract: Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 25, 2024
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20230373960
    Abstract: Disclosed herein are novel pharmaceutically active compounds and their preparation methods. The compounds inhibit mutant EGFR and are useful in the treatment of oncological diseases.
    Type: Application
    Filed: September 22, 2021
    Publication date: November 23, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230322761
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: March 10, 2021
    Publication date: October 12, 2023
    Inventors: Hexiang WANG, Bailin LEI, Changxin HUO, Dongqing SUN, Jie CHEN, Zhiwei WANG
  • DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230265116
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 24, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230248834
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 10, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230167118
    Abstract: Bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 1, 2023
    Inventors: Hexiang WANG, Bailin LEI, Changxin HUO, Dongqing SUN, Jie CHEN, Zhiwei WANG, Yucheng WANG